- A study in Scotland found that after only one injection of COVID-19, people’s risk of hospitalization is greatly reduced.
- This large study monitored people injected with Pfizer-BioNTech and AstraZeneca-Oxford.
- This is the latest in a series of promising updates about the effectiveness of vaccines in the real world.
- Visit the “Business” section of Insider for more stories.
According to the latest data from Scotland, the two COVID-19 vaccines authorized for use in the UK seem to greatly reduce the risk of people being hospitalized from the coronavirus in a single injection.
The figures released earlier on Monday were the first to measure hospitalization rates from actual vaccine launches.
This is a series of promising latest updates in countries that have already vaccinated a large part of the population.
Among them, more than 1.1 million people received a dose of a vaccine developed by Pfizer and BioNTech, or a dose of vaccine developed by AstraZeneca and Oxford University.
Scientists have found that people who are vaccinated are much less likely to be hospitalized than people who are not.
From an overall protection perspective, the study estimates that within four weeks after receiving a jab, the risk of hospitalization for COVID-19 dropped by a total of 84%.
Britain decided to give priority to giving as many people as possible a jab. As a result, although the manufacturers of the two vaccines recommend that the two doses be separated by a certain time interval to provide the most adequate protection, few people in the UK have received a second dose.
Breaking down the data, a dose of Pfizer-BioNTech vaccine reduces the risk of hospitalization from COVID-19 (compared to unvaccinated people) by 85% compared to four weeks after the first jab, while the AstraZeneca vaccine is in the same period as 94 Percentage of risk of hospitalization.
Scientists measure the effectiveness of the vaccine every week after receiving the first dose of vaccine. They found the strongest “vaccine effect” in the fourth week after vaccination.
The vaccine has the highest effect in people between 18 and 64 years of age. However, in this age group, only those who are defined as clinically vulnerable are eligible to receive the vaccine.
People over the age of 80 have the highest risk of COVID-19. After four weeks, the risk of hospitalization with these vaccines has been reduced by 81%.
This research is published as a preprint; the next step will be peer review.
Scientists describe it as the first study to study the impact of vaccines on hospitalizations throughout the country.
Real-world data from the Israeli vaccination campaign previously found that the use of two doses of Pfizer-BioNTech vaccine reduced the number of symptomatic cases by 94%, a separate measure of effectiveness.
Aziz Sheik, chief scientist at the University of Edinburgh, said the latest evidence “gives us reason for optimism.”